OBJECTIVE: Accumulating evidence indicates an important role of neutrophils in the development of rheumatoid arthritis (RA). Recruitment of neutrophils to the joint space and release of proteolytic enzymes can exacerbate tissue damage and the inflammatory response related to RA. Engagement of beta2 integrin and subsequent activation of downstream signaling have been shown to be fundamental for activation of neutrophil effector functions. The aim of this study was to test the hypothesis that Vav and phospholipase Cgamma2 (PLCgamma2), two molecules involved in integrin signaling, are required for arthritis generation and neutrophil activation in a mouse model of arthritis. METHODS: Arthritis was induced in wild-type (WT), Vav(null), and PLCgamma2(-/-) mice using the K/BxN serum-transfer model. Neutrophil function was assessed by analyses of adhesion, spreading, and degranulation on integrin-dependent substrates. Regulation of integrin signaling was determined by analyzing the phosphorylation of Pyk-2, Src, and ERK. RESULTS: Vav(null) and PLCgamma2(-/-) mice were protected from inflammation and bone erosion in the K/BxN serum-transfer model of arthritis. Mechanistically, Vav and PLCgamma2 control neutrophils mediated spreading and degranulation on integrin-dependent substrates. Consequently, the Vav/PLCgamma2 axis, acting downstream of the integrin receptor, modulated the activation of Pyk-2, Src, and ERK. CONCLUSION: Our findings show that Vav cooperates with PLCgamma2 in modulating neutrophil activation downstream of the integrin receptor. This study identifies a Vav/PLCgamma2-dependent signaling pathway as a possible therapeutic target for the treatment of inflammation and bone disruption in arthritis.
OBJECTIVE: Accumulating evidence indicates an important role of neutrophils in the development of rheumatoid arthritis (RA). Recruitment of neutrophils to the joint space and release of proteolytic enzymes can exacerbate tissue damage and the inflammatory response related to RA. Engagement of beta2 integrin and subsequent activation of downstream signaling have been shown to be fundamental for activation of neutrophil effector functions. The aim of this study was to test the hypothesis that Vav and phospholipase Cgamma2 (PLCgamma2), two molecules involved in integrin signaling, are required for arthritis generation and neutrophil activation in a mouse model of arthritis. METHODS:Arthritis was induced in wild-type (WT), Vav(null), and PLCgamma2(-/-) mice using the K/BxN serum-transfer model. Neutrophil function was assessed by analyses of adhesion, spreading, and degranulation on integrin-dependent substrates. Regulation of integrin signaling was determined by analyzing the phosphorylation of Pyk-2, Src, and ERK. RESULTS:Vav(null) and PLCgamma2(-/-) mice were protected from inflammation and bone erosion in the K/BxN serum-transfer model of arthritis. Mechanistically, Vav and PLCgamma2 control neutrophils mediated spreading and degranulation on integrin-dependent substrates. Consequently, the Vav/PLCgamma2 axis, acting downstream of the integrin receptor, modulated the activation of Pyk-2, Src, and ERK. CONCLUSION: Our findings show that Vav cooperates with PLCgamma2 in modulating neutrophil activation downstream of the integrin receptor. This study identifies a Vav/PLCgamma2-dependent signaling pathway as a possible therapeutic target for the treatment of inflammation and bone disruption in arthritis.
Authors: Regina A Clemens; Laurie E Lenox; Taku Kambayashi; Natalie Bezman; Jonathan S Maltzman; Kim E Nichols; Gary A Koretzky Journal: J Immunol Date: 2007-04-01 Impact factor: 5.422
Authors: Daniel B Graham; Marina Cella; Emanuele Giurisato; Keiko Fujikawa; Ana V Miletic; Tracie Kloeppel; Karry Brim; Toshiyuki Takai; Andrey S Shaw; Marco Colonna; Wojciech Swat Journal: J Immunol Date: 2006-08-15 Impact factor: 5.422
Authors: Cinzia Giagulli; Linda Ottoboni; Elena Caveggion; Barbara Rossi; Clifford Lowell; Gabriela Constantin; Carlo Laudanna; Giorgio Berton Journal: J Immunol Date: 2006-07-01 Impact factor: 5.422
Authors: Ana V Miletic; Daniel B Graham; Vivianne Montgrain; Keiko Fujikawa; Tracie Kloeppel; Karry Brim; Brian Weaver; Robert Schreiber; Ramnik Xavier; Wojciech Swat Journal: Blood Date: 2006-12-07 Impact factor: 22.113
Authors: Kaihua Zhang; Seokho Kim; Viviana Cremasco; Angela C Hirbe; Lynne Collins; David Piwnica-Worms; Deborah V Novack; Katherine Weilbaecher; Roberta Faccio Journal: Cancer Res Date: 2011-05-20 Impact factor: 12.701
Authors: Laurie E Lenox; Taku Kambayashi; Mariko Okumura; Christopher Prieto; Karsten Sauer; Ralph M Bunte; Martha S Jordan; Gary A Koretzky; Kim E Nichols Journal: J Allergy Clin Immunol Date: 2009-11 Impact factor: 10.793
Authors: Corinne E Decker; Zhengfeng Yang; Ryan Rimer; Kyung-Hyun Park-Min; Claudia Macaubas; Elizabeth D Mellins; Deborah V Novack; Roberta Faccio Journal: Proc Natl Acad Sci U S A Date: 2015-12-07 Impact factor: 11.205